Clinical Trial Update: JDQ443 for KRAS G12C NSCLC Brain Metastases [Phase 2]

View source ↗

Summary

A Phase 2 trial of JDQ-443 for KRAS G12C-mutant non-small cell lung cancer with brain metastases has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Non-small Cell Lung Cancer

Drugs mentioned

• JDQ-443 (JDQ-443)

Snippet

Sponsor: Maastricht University Medical Center | Conditions: Non Small Cell Lung Cancer Metastatic, Brain Metastases, Adult | Phase 2 | Status: WITHDRAWN